KMB

Business Context and Reporting Period

Company: Kimberly-Clark Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2009
Business Overview: A multinational manufacturer of personal care, consumer tissue, professional, and health care products. The company operates four global segments: Personal Care, Consumer Tissue, K-C Professional & Other, and Health Care.

Key Financial Metrics

Note: Total Debt calculated as Debt payable within one year ($1,314) plus Long-Term Debt ($4,875) for Q1 2009.

Material Changes vs. Prior Period

• Revenue Decline: Net sales decreased 6.6% year-over-year. The decline was driven by a 10% negative currency impact and a 3% volume decrease, partially offset by a 6% increase in net selling prices.
• Profitability Pressure: Operating profit fell 5.4% to $628 million. While input cost deflation ($75 million benefit) and cost savings ($45 million benefit) helped, they were outweighed by production curtailments ($90 million negative impact) and currency losses ($150 million negative impact).
• Currency Impact: Significant currency transaction losses of $76 million occurred in Q1 2009 (vs. $12 million gains in 2008), largely due to exchange restrictions in Venezuela and the weakening of the Euro, South Korean Won, and Mexican Peso.
• Working Capital: Cash flow from operations surged 55.9% to $692 million, primarily due to a $156 million decrease in operating working capital, specifically a reduction in inventory levels exceeding $300 million.
• Segment Performance:
  • Personal Care: Sales down 3.4%; Operating profit up 3.3%.
  • Consumer Tissue: Sales down 7.8%; Operating profit up 24.4% (driven by price increases and cost deflation).
  • K-C Professional & Other: Sales down 14.5%; Operating profit down 17.5% (impacted by economic weakness and unemployment).
  • Health Care: Sales flat; Operating profit up 4.3%.

Guidance, Outlook, and Risks

• 2009 Guidance: Management maintains an earnings per share (EPS) guidance range of $4.00 to $4.20 for the full year 2009, despite changes in planning assumptions regarding currency and inventory.
• Outlook: Economic weakness continues to negatively impact demand. The company anticipates higher production curtailments to further improve inventory levels. Currency effects are expected to remain more negative than initially anticipated.
• Capital Allocation: Capital spending for the quarter was $211 million, in line with a full-year target of $800–$850 million. No common stock repurchases were made in Q1 2009; the company does not anticipate purchasing shares in 2009.
• Acquisitions: The company acquired the remaining 31% interest in its Andean subsidiary (Colombiana Kimberly Colpapel S.A.) for $289 million, recorded as an equity transaction.
• Risks: Key risks include foreign currency exchange rate fluctuations, raw material and energy price volatility, competitive pressures, and economic conditions affecting consumer demand.

Investor Verification Checklist

• Currency Exposure: Verify the magnitude of currency transaction losses ($76 million) and the specific impact of the Venezuelan exchange restrictions on future cash flows.
• Inventory Levels: Confirm the sustainability of the $300+ million inventory reduction and whether production curtailments will continue to impact revenue growth.
• Input Cost Trends: Monitor the trajectory of fiber and polymer resin costs to assess if the $75 million deflation benefit is sustainable.
• EPS Guidance: Track quarterly performance against the $4.00–$4.20 full-year EPS target given the headwinds from currency and volume.
• Debt Structure: Review the increase in total debt to $6.2 billion and the company's ability to service debt amidst lower operating profits.